iBio Stock Forecast, Price & News

iBio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Is iBio a buy right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" iBio stock.
View analyst ratings for iBio or view top-rated stocks.

When is iBio's next earnings date?

iBio is scheduled to release its next quarterly earnings announcement on Monday, February 14th 2022.
View our earnings forecast for iBio.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) posted its quarterly earnings data on Monday, November, 15th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.05) by $0.01. The biotechnology company had revenue of $0.21 million for the quarter. iBio had a negative net margin of 1,133.19% and a negative trailing twelve-month return on equity of 33.06%.
View iBio's earnings history.

When did iBio's stock split? How did iBio's stock split work?

iBio shares reverse split on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 8th 2018. An investor that had 100 shares of iBio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

2 brokerages have issued 12-month price objectives for iBio's shares. Their forecasts range from $1.50 to $3.00. On average, they anticipate iBio's stock price to reach $2.25 in the next twelve months. This suggests a possible upside of 368.8% from the stock's current price.
View analysts' price targets for iBio or view top-rated stocks among Wall Street analysts.

Who are iBio's key executives?

iBio's management team includes the following people:

• Thomas F. Isett, Executive Chairman, President & CEO
• Randy J. Maddux, Chief Operating Officer
• Robert M. Lutz, Chief Financial & Business Officer
• Martin B. Brenner, Chief Scientific Officer
• James Abbey, Vice President-Strategic Business Development

Who are some of iBio's key competitors?

Some companies that are related to iBio include Aadi Bioscience (AADI), Vera Therapeutics (VERA), Pliant Therapeutics (PLRX), Verona Pharma (VRNA), Adicet Bio (ACET), Arbutus Biopharma (ABUS), Mersana Therapeutics (MRSN), Oramed Pharmaceuticals (ORMP), CytoDyn (CYDY), Allakos (ALLK), Rhythm Pharmaceuticals (RYTM), Dyne Therapeutics (DYN), Marinus Pharmaceuticals (MRNS), Spero Therapeutics (SPRO) and Rigel Pharmaceuticals (RIGL).
View all of IBIO's competitors.

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia (NOK) and Moderna (MRNA).

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

Who are iBio's major shareholders?

iBio's stock is owned by a variety of retail and institutional investors. Top institutional investors include Cutler Group LP (0.00%). Company insiders that own iBio stock include Eastern Capital Ltd, James P Mullaney and Robert L Erwin.
View institutional ownership trends for iBio.

Which major investors are selling iBio stock?

IBIO stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP.
View insider buying and selling activity for iBio or view top insider-selling stocks.

How do I buy shares of iBio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $0.48.

How much money does iBio make?

iBio has a market capitalization of $104.62 million and generates $2.37 million in revenue each year. The biotechnology company earns $-23.21 million in net income (profit) each year or ($0.12) on an earnings per share basis.

How many employees does iBio have?

iBio employs 47 workers across the globe.

What is iBio's official website?

The official website for iBio is www.ibioinc.com.

Where are iBio's headquarters?

iBio is headquartered at 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at (302) 355-0650, via email at [email protected], or via fax at 302-356-1173.